No Data
No Data
HC Wainwright & Co. : Maintaining the Trevena (TRVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $5.00.
HC Wainwright & Co. : Maintaining the Trevena (TRVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $5.00.
HC Wainwright & Co. Maintains Buy on Trevena, Lowers Price Target to $5
HC Wainwright & Co. analyst Douglas Tsao maintains Trevena (NASDAQ:TRVN) with a Buy and lowers the price target from $9 to $5.
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising Drug TRV045
Trevena Inc. Under Fire: Unregistered Equity Sales Risk Legal Woes and Market Trust
Analysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)
Trevena (TRVN.US): The 2024 Q1 financial report achieved revenue of 20,000 US dollars, the previous value was 6,000 US dollars; earnings per share were -0.36 US dollars, previous value was -0.81 US dollars, and the expected value was -0.47 US dollars.
Trevena (TRVN.US): The 2024 Q1 financial report achieved revenue of 20,000 US dollars, the previous value was 6,000 US dollars; earnings per share were -0.36 US dollars, previous value was -0.81 US dollars, and the expected value was -0.47 US dollars.